

2013

英文論文

1. 2013 **Kudo M**: Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013. **Oncology** 84: 1-2, 2013 (IF=2.152).
2. 2013 Fujimoto K, Kato M, **Kudo M**, Yada N, Shiina T, Ueshima K, Yamada Y, Ishida T, Azuma M, Ymasaki M, Yamamoto K, Hayashi N, Takehara T: Novel image analysis method using ultrasound elastography for non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C. **Oncology** 84: 3-12, 2013 (IF=2.152).
3. 2013 Yada N, Morikawa H, Fujimoto K, Kato M, Kawada N, **Kudo M**: Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. **Oncology** 84: 13-20, 2013 (IF=2.152).
4. 2013 **Kudo M**, Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Aii S: Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) in the management of hepatocellular carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan. **Oncology** 84: 21-27, 2013 (IF=2.152).
5. 2013 Inoue T, **Kudo M**, Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Ueshima k, Nishida N: Usefulness of contrast-enhanced ultrasonography to evaluate the post treatment responses of radiofrequency ablation for hepatocellular carcinoma; comparison with dynamic CT. **Oncology** 84: 51-57, 2013 (IF=2.152).

6. 2013 Minami Y, **Kudo M**: Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: US, CT and MRI. **Oncology** 84: 58-63, 2013 (IF=2.152).
7. 2013 Minata M, Harada K, **Kudo M**, Ikai I, Nishida N: The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection. **Oncology** 84: 75-81, 2013 (IF=2.152).
8. 2013 Nishida N, Arizumi T, Takita M, Nagai T, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ida H, **Kudo M**: Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. **Oncology** 84: 82-87, 2013 (IF=2.152).
9. 2013 Minata M, **Kudo M**, Harada K, Ikai I, Nishida N: Expression of E-cadherin and vascular endothelial growth factor in non-cancerous liver is associated with recurrence of HCC after curative resection. **Oncology** 84: 88-92, 2013 (IF=2.152).
10. 2013 Nishida N, **Kudo M**: Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. **Oncology** 84: 93-97, 2013 (IF=2.152).
11. 2013 Claudon M, Dietrich CF, Choi BI, Cosgrove DO, **Kudo M**, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. **Ultrasound Med Biol** 39: 187-210, 2013 (IF=2.298).

12. 2013 Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, **Kudo M**, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan.: Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. **J Hepatol** 58: 724-729, 2013 (IF=10.590).
13. 2013 Sakurai T, **Kudo M**, Umemura A, He G, Elsharkawy AM, Seki E, Karin M: p38 α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. **Cancer Res** 73: 215-224, 2013 (IF=8.556).
14. 2013 Claudon M, Dietrich CF, Choi BI, Cosgrove DO, **Kudo M**, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. **Ultraschall Med**, 34: 11-29, 2013 (IF=4.434).
15. 2013 Watanabe T, Yamashita K, Sakurai T, **Kudo M**, Shiokawa M, Uza N, Kadoma Y, Uchida K, Okazaki K, Chiba T: Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. **J Gastroenterol**, 48: 247-253, 2013 (IF=4.414).
16. 2013 Nagata Y, **Kudo M**, Nagai T, Watanabe T, Kawasaki M, Asakuma Y, Hagiwara S, Nishida N, Matsui S, Kashida H, Sakurai T: Heat shock protein 27 expression is inversely correlated with atrophic gastritis and intraepithelial neoplasia. **Digest Dis Sci**, 58: 381-388, 2013 (IF=2.516).
17. 2013 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh

KL, Han KH, **Kudo M**, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Ceng AL: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). **Liver Int**, 33: 327-337, 2013 (IF=4.470).

18. 2013 Minami Y, **Kudo M**: Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. **Gut Liver**, 7: 1-6, 2013 (IF=2.000).

19. 2013 Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa K, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Hidenori Toyoda, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arie S, Nishio K, **Kudo M**: FGF3/FGF4 Amplification and Multiple lung Metastases in responders to sorafenib in hepatocellular carcinoma. **Hepatology**, 57: 1407-1415, 2013 (IF=11.711).

20. 2013 Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwar E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi K, Katsushima S, **Kudo M**, Takaguchi K, Hiasa Y, Chayama K, Yatsushashi H, Oketani M, Kumada H: Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. **J Gastroenterol**, 48: 382-390, 2013 (IF=4.414).

21. 2013 Takayasu K, Arie S, Sakamoto M, Matsuyama Y, **Kudo M**, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study Group of Japan: Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. **Liver Int**, 33: 762-770, 2013 (IF=4.470).

22. 2013 Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y,

Kogita S, Kumano S, **Kudo M**, Mochizuki T: Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. **Radiology**, 266: 480-490, 2013 (IF=6.798).

23. 2013 Hagiwara S, **Kudo M**, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada Y, Nishida N: Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. **J Med Virol**, 85: 987-95, 2013 (IF=1.998).
24. 2013 **Kudo M**: Early Hepatocellular Carcinoma: Definition and Diagnosis. **Liver Cancer** 2(2): 69-72, 2013 (IF=0.000).
25. 2013 Matsui S, Kashida H, **Kudo M**: Senile systemic amyloidosis localized to the stomach. **Digest Endosc** 25: 468-469, 2013 (IF=2.715).
26. 2013 Mine H, Sakurai T, Kashida H, Matsui S, Nishida N, Nagai T, Hagiwara S, Watanabe T, **Kudo M**: Association of gankyrin and stemness factor expression in human colorectal cancer. **Dig Dis Sci** 58: 2337-2344, 2013 (IF=2.516).
27. 2013 Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, **Kudo M**, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y: A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization. **Eur J Cancer** 49: 2832-2840, 2013 (IF=6.163).
28. 2013 Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H, **Kudo M**: Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. **World J Gastroenterol** 19: 5706-5712, 2013 (IF=2.787).

29. 2013 **Kudo M**: [Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013. **Digest Dis** 31: 405-407, 2013 (IF=1.777).
30. 2013 Nishida N, Iwamura S, Ida H, Hagiwara S, Kagioka Y, Minami Y, Maetani Y, Itoh K, **Kudo M**: Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases. **Digest Dis** 31: 408-414, 2013 (IF=1.777).
31. 2013 Yada N, **Kudo M**, Chung H, Watanabe T: Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis. **Digest Dis** 31: 415-420, 2013 (IF=1.777).
32. 2013 Sugimoto K, Kim SR, Shamy AE, Imoto S, Ando K, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Takashi H, Hotta H, Hayashi Y, **Kudo M**: Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance. **Digest Dis** 31: 421-425, 2013 (IF=1.777).
33. 2013 Kim SR, Shamy AE, Imoto S, Kim KI, Sugimoto K, Kim SK, Tanaka Y, Hatae T, Hasegawa Y, Fujinami A, Ohta M, Hotta H, **Kudo M**: Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load. **Digest Dis** 31: 426-433, 2013 (IF=1.777).
34. 2013 Sugimoto K, Kim SR, Shamy AE, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, **Kudo M**: Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy. **Digest Dis** 31: 434-439, 2013 (IF=1.777).
35. 2013 Sakurai T, **Kudo M**, Watanabe T, Itoh K, Higashitsuji H, Arizumi T, Inoue T, Hagiwara S, Ueshima K, Nishida N, Fukumoto M, Fujita J: Hypothermia Protects against Fulminant Hepatitis in Mice by

Reducing Reactive Oxygen Species Production. **Digest Dis** 31: 440-446, 2013 (IF=1.777).

36. 2013 Nishida N, **Kudo M**: Oxidative stress and epigenetic instability in human hepatocarcinogenesis. **Digest Dis** 31: 447-453, 2013 (IF=1.777).
37. 2013 Kim SK, Marusawa H, Eso Y, Chiba T, **Kudo M**: Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations. **Digest Dis** 31: 454-458, 2013 (IF=1.777).
38. 2013 Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, **Kudo M**: Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. **Digest Dis** 31: 459-466, 2013 (IF=1.777).
39. 2013 Tsuji N, Ishiguro S, Sasaki Y, **Kudo M**: CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. **Digest Dis** 31: 467-471, 2013 (IF=1.777).
40. 2013 Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, **Kudo M**: Hypovascular hepatic nodules showing hypointense on the hepatobiliary phase image of Gd-EOB-DTPA enhanced MRI to develop a hyper-vascular hepatocellular carcinoma: a nationwide retrospective study on their Natural course and Risk factors. **Digest Dis** 31: 472-479, 2013 (IF=1.777).
41. 2013 Minami Y, Hayaishi S, **Kudo M**: Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding? **Digest Dis** 31: 480-484, 2013 (IF=1.777).

42. 2013 Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Hori M, **Kudo M**, Murakami T: Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma. **Digest Dis** 31: 485-489, 2013 (IF=1.777).
43. 2013 **Kudo M**, Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T, the Osaka Liver Cancer Study Group: Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. **Digest Dis** 31: 490-498, 2013 (IF=1.777).
44. 2013 **Kudo M**: Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma? **Liver Cancer** 2(3-4):151-152, 2013 (IF=0.000).
45. 2013 Sakurai T, **Kudo M**: Molecular link between liver fibrosis and hepatocellular carcinoma. **Liver Cancer** 2(3-4):365-366, 2013 (IF=0.000).
46. 2013 Das K, **Kudo M**, Kitano M, Sakamoto H, Komaki T, Takagi T, Yamao K: Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions. **J Med Ultrason** 40:211-218, 2013 (IF=0.559).
47. 2013 **Kudo M**, Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T: JSUM ultrasound elastography practice guidelines: liver. **J Med Ultrason** 40: 325-357, 2013 (IF=0.559).
48. 2013 Kagawa Y, Okada M, Yagyu Y, Kumano S, Kanemitsu M, **Kudo M**, Murakami T: Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphasic fast CT imaging technique. **Acta Radiol** 54: 843-850, 2013 (IF=2.009).

49. 2013 Nouse K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, **Kudo M**, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, the Liver Cancer Study Group of Japan: Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. **Brit J Cancer** 109: 1904-1907, 2013 (IF=5.569).
50. 2013 Cheng AL, Kang YK, Lin DY, Park JW, **Kudo M**, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzaone S, Yang L, Lechuga MJ, Raymond E, for the SUN1170 HCC Study Group: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. **J Clin Oncol** 10; 31: 4067-4075, 2013 (IF=18.021).
51. 2013 Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Avina JR, **Kudo M**, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL: Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3 BRISK-FL study. **J Clin Oncol** 1; 31: 3517-3524, 2013 (IF=18.021).
52. 2013 Llovet JM, Decaens T, Raoul JL, Boucher E, **Kudo M**, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW: Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib failed results from the randomized phase 3 BRISK-PS study. **J Clin Oncol** 1; 31: 3509-3516, 2013 (IF=18.021).
53. 2013 Nishida N, **Kudo M**, Nishimura T, Arizumi T, Takita M, Kitai S,

Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A: Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. **Plos One** 8(9):e72312, 2013 (IF=3.057).

54. 2013 Taki H, Sakamoto T, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T: Real-time high-resolution vascular ultrasound using frequency domain interferometry with the ROI-division process. **Conf Proc IEEE Eng Med Biol Soc** 1398-1401, 2013 (IF=0.000).